Edgewise Therapeutics director Fox acquires 308 shares

Edgewise Therapeutics, Inc. director Jonathan C. Fox acquired 308 shares of common stock through restricted stock units granted and released on October 1, 2026, as a Quarterly Retainer Award under the company’s Outside Directors Compensation Policy.

Rhea-AI Filing Summary

Edgewise Therapeutics, Inc. director Jonathan C. Fox acquired 308 shares of common stock through restricted stock units granted and released on October 1, 2026, as a Quarterly Retainer Award under the company’s Outside Directors Compensation Policy. His reported direct holdings after the transaction were 25,141 shares.

Insider Trade Summary

Grant/Award: 308 shares

Grant/Award 1 txn

Insider Fox Jonathan C

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	308	$0.00	$0.00

Holdings After Transaction: Common Stock — 25,141 shares (Direct)

Key Figures

Shares acquired: 308 shares Direct holdings after transaction: 25,141 shares

2 metrics

Shares acquired 308 shares Granted and released October 1, 2026, as a Quarterly Retainer Award

Direct holdings after transaction 25,141 shares Jonathan C. Fox’s reported position

Key Terms

restricted stock units, Quarterly Retainer Award, Outside Directors Compensation Policy

3 terms

restricted stock units financial

"restricted stock units granted and released"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

Quarterly Retainer Award financial

"as a Quarterly Retainer Award"

Outside Directors Compensation Policy financial

"pursuant to Section 2.4 of the Outside Directors Compensation Policy"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many shares did Edgewise Therapeutics (EWTX) director Jonathan C. Fox acquire?

Jonathan C. Fox acquired 308 shares on October 1, 2026, through restricted stock units granted and released as a Quarterly Retainer Award.

How many Edgewise Therapeutics (EWTX) shares did Jonathan C. Fox hold after the award?

Fox’s reported direct holdings after the transaction were 25,141 shares.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 10/02/2026 - 04:47 PM Accepted by SEC EDGAR 10/02/2026 - 04:47 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Fox Jonathan C

(Last) (First) (Middle)

C/O EDGEWISE THERAPEUTICS, INC.

1715 38TH STREET

(Street)

BOULDER COLORADO 80301

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Edgewise Therapeutics, Inc. [ EWTX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
10/01/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	10/01/2026		A		308	A	$0.00	25,141	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

Remarks:

Consists of restricted stock units granted and released to the reporting person on October 1, 2026, as a Quarterly Retainer Award pursuant to Section 2.4 of the Edgewise Therapeutics, Inc. Outside Directors Compensation Policy, as amended.

	/s/ John R. Moore, Attorney-in-Fact for Fox Jonathan C	10/01/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)